WaveMan
WaveMan · Company
ARTV · Artiva Biotherapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ARTV Artiva Biotherapeutics (ARTV) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001817241
Quote by TradingView
Cluster · 5 insidersForm 144 · 4
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
66
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $11.0K priced

What the filings say about ARTV

Insiders, 180 days
+$106.7M net bought
5 buyers · 5 sellers · 24% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$609.7K
4 notices

Artiva Biotherapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Artiva Biotherapeutics, Inc. insiders bought a net $106.7M of stock across 51 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Aslan Fred
Chief Executive Officer
SELL
2026-10-07 SECtraded 2026-10-06
23,463
$168.9K
-9.4%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Oct 5, 2026.
  • The trade is 1.5% of the 1,519,606 shares held after it.
  • 3 other insiders sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Aslan Fred sold about $168.9K of ARTV under a 10b5-1 plan on Oct 6, 2026; 3 other insiders sold within 30 days and 66 funds added in the latest 13F quarter.
Banerjee Subhashis
Chief Medical Officer
SELL
2026-10-06 SECtraded 2026-10-05
1,099
$7.5K
-12.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Sep 3, 2026.
  • The trade is 0.6% of the 169,848 shares held after it.
  • 3 other insiders sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Banerjee Subhashis sold about $7.5K of ARTV on Oct 5, 2026; 3 other insiders sold within 30 days and 66 funds added in the latest 13F quarter.
Aslan Fred
Chief Executive Officer
SELL
2026-10-06 SECtraded 2026-10-05
61,696
$421.8K
-12.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 8, 2026.
  • The trade is 4.0% of the 1,543,069 shares held after it.
  • 3 other insiders sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Aslan Fred sold about $421.8K of ARTV on Oct 5, 2026; 3 other insiders sold within 30 days and 66 funds added in the latest 13F quarter.
Horan Christopher
Chief Tech Operations Officer
SELL
2026-10-06 SECtraded 2026-10-05
10,340
$70.7K
-12.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 3, 2026.
  • The trade is 3.3% of the 312,744 shares held after it.
  • 3 other insiders sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Tech Operations Officer Horan Christopher sold about $70.7K of ARTV on Oct 5, 2026; 3 other insiders sold within 30 days and 66 funds added in the latest 13F quarter.
Bush Jennifer
COO, CLO, Compliance Officer
SELL
2026-10-06 SECtraded 2026-10-05
8,370
$57.2K
-12.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 3, 2026.
  • The trade is 2.3% of the 366,159 shares held after it.
  • 3 other insiders sold within 30 days.
  • 66 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO, CLO, Compliance Officer Bush Jennifer sold about $57.2K of ARTV on Oct 5, 2026; 3 other insiders sold within 30 days and 66 funds added in the latest 13F quarter.
51 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 46 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$106.7M over 180 days
-$1.5M over 90 days · +$109.2M of it by a 10%+ holder
more than 99% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
66 funds bought in last quarter
more than 54% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.8% of the float short (float per yahoo 2026-10-26) · 3.7 days to cover · settled 2026-09-30
below 51% of Pharma & Biotech
The situation: each line is one rule over one dataset
5 insiders bought a net $106.7M while the stock fell 43% over six months, but 4 Form 144 notices ($609.7K) are queued to sell.
What changed in the last 30 days
Oct 7Chief Executive Officer Aslan Fred sold $168.9K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6Chief Executive Officer Aslan Fred sold $421.8K (Oct 5)
Oct 6Director FRED ASLAN filed to sell $245.7K by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 6Chief Tech Operations Officer Horan Christopher sold $70.7K (Oct 5)
Oct 6COO, CLO, Compliance Officer Bush Jennifer sold $57.2K (Oct 5)

Watch ARTV

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+37.5%12M
-31%+45%+122%+199%2025-102025-122026-022026-042026-062026-082026-10 2026-05-11 · RA Capital Nexus Fund III, L.P. bought $75.0M2026-05-11 · GC Corp. bought $12.5M2026-06-11 · RA Capital Nexus Fund, L.P. bought $4.3M2026-05-11 · GC Corp. bought $4.0M2026-06-12 · Kolchinsky Peter bought $3.4M2026-06-09 · RA Capital Nexus Fund, L.P. bought $3.3M2026-07-16 · RA CAPITAL MANAGEMENT, L.P. bought $1.4M2026-07-21 · RA CAPITAL MANAGEMENT, L.P. bought $1.2M2026-06-16 · Kolchinsky Peter bought $1.1M2026-07-22 · RA CAPITAL MANAGEMENT, L.P. bought $835.4K2026-09-03 · Aslan Fred sold $690.4K2026-07-23 · RA CAPITAL MANAGEMENT, L.P. bought $596.4K2026-10-05 · Aslan Fred sold $421.8K2026-07-24 · RA CAPITAL MANAGEMENT, L.P. bought $412.8K2026-06-25 · RA CAPITAL MANAGEMENT, L.P. bought $275.3K2026-09-08 · Aslan Fred sold $255.7K2026-07-31 · RA CAPITAL MANAGEMENT, L.P. bought $247.7K2026-05-19 · Aslan Fred sold $244.3K2026-07-29 · RA CAPITAL MANAGEMENT, L.P. bought $208.0K2026-10-06 · Aslan Fred sold $168.9K2026-06-15 · Kolchinsky Peter bought $138.6K2026-07-10 · RA CAPITAL MANAGEMENT, L.P. bought $135.5K2026-09-03 · Horan Christopher sold $115.6K2026-08-27 · Banerjee Subhashis sold $98.7K2026-09-03 · Bush Jennifer sold $93.6K2026-05-19 · Bush Jennifer sold $79.2K2026-10-05 · Horan Christopher sold $70.7K2026-07-17 · RA CAPITAL MANAGEMENT, L.P. bought $70.5K2026-05-19 · Banerjee Subhashis sold $63.4K2026-05-19 · Horan Christopher sold $63.1K2026-07-13 · RA CAPITAL MANAGEMENT, L.P. bought $58.6K2026-07-13 · RA CAPITAL MANAGEMENT, L.P. bought $58.3K2026-10-05 · Bush Jennifer sold $57.2K2026-05-19 · Raymon Heather sold $27.9K2025-11-17 · Aslan Fred sold $21.5K2025-12-15 · Aslan Fred sold $19.1K2026-06-26 · RA CAPITAL MANAGEMENT, L.P. bought $16.8K2026-09-03 · Banerjee Subhashis sold $12.3K2026-10-05 · Banerjee Subhashis sold $7.5K2026-08-18 · Banerjee Subhashis sold $5.1K2026-06-10 · RA Capital Nexus Fund, L.P. bought $7212026-10-06 · FRED ASLAN filed to sell $245.7K2026-09-08 · FRED ASLAN filed to sell $262.2K2026-08-27 · SUBHASHIS BANERJEE filed to sell $92.0K2026-08-18 · SUBHASHIS BANERJEE filed to sell $9.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ARTV: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
17,955,642 sh
$174.2M
VIKING GLOBAL INVESTORS LP
2,604,166 sh
$25.3M
Blackstone Inc.
2,403,437 sh
$23.3M
5AM Venture Management, LLC
2,353,304 sh
$22.8M
Venrock Adviser, LLC
2,043,596 sh
$19.8M

Congress trades in ARTV

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ARTV planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
FRED ASLAN
Filed 2026-10-06
$245.7K
FRED ASLAN
Filed 2026-09-08
$262.2K
SUBHASHIS BANERJEE
Filed 2026-08-27
$92.0K
SUBHASHIS BANERJEE
Filed 2026-08-18
$9.8K

ARTV mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$983.1K position · as of 2026-06-30
1.3%
Ultra-Small Company Fund
$485.0K position · as of 2026-06-30
0.5%
Franklin Biotechnology Discovery Fund
$5.5M position · as of 2026-07-31
0.5%
Ultra-Small Company Market Fund
$339.5K position · as of 2026-06-30
0.2%
Franklin Small Cap Growth Fund
$4.6M position · as of 2026-07-31
0.2%
Nationwide Bailard Small Cap Value Fund
$209.1K position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
1 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $106.7M bought by insiders over 180 days, 66 funds added last quarter, $609.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ARTV financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$251.0K
four quarters, 2024-01-01 to 2024-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$76.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-36.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-37.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-25.5%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$0$251.0K$33.5M
Operating income-$89.8M-$67.3M-$30.7M
Net income-$83.9M-$65.4M-$28.7M
EPS (diluted)-3.43-5.81-35.78
Operating cash flow-$76.8M-$55.0M-$47.4M
Cash$26.7M$40.2M$53.5M
SEC XBRL, fiscal years, as known on 2026-10-27

ARTV Stock Sonar score 5/7 axes

Find similar shapesCompare

ARTV ranks highest on insider conviction (98th percentile) and profitability (61st), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
61
Inputs
  • Return on equity-36.6% · 63 pct, sector of 545
  • Return on assets-33.8% · 57 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-37.5% · 62 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
98
Inputs
  • Net Form 4 buying (codes P and S), 180d$107.2M · 99 pct, sector of 428
  • Insider buyers, 180d5 · 97 pct, sector of 437
Institutional and government
54
Inputs
  • Funds adding, latest quarter66 · 54 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
54
Inputs
  • Short interest, % of float+11.8% · 34 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.7% · 73 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ARTV filings, in plain words

Are Artiva Biotherapeutics insiders buying or selling ARTV?

In the 180 days to 2026-10-27, Artiva Biotherapeutics insiders were net buyers, a net $106.7M: $109.2M of purchases and $2.5M of sales reported on Form 4, by 5 buyers and 5 sellers.

Are there planned insider sales of ARTV?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $609.7K of stock; the latest, by FRED ASLAN, was filed 2026-10-06.

Read the full summary

In the 180 days to 2026-10-27, Artiva Biotherapeutics insiders were net buyers of ARTV, a net $106.7M across purchases and sales reported on Form 4 by 5 buyers and 5 sellers. Most of that figure, $109.2M, came from a holder of 10% or more rather than an officer or director. Purchases outweighed sales more than tenfold by value. 5 insiders reported purchases in that window. 24% of the 17 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $609.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies